Somatostatin receptor-based cancer therapy
US10493162B2 · kind B2 · utility
0Cited by
2References
26Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 12, 2017 |
| Grant date | Dec 3, 2019 |
| Priority date | — |
| Expiry date | Sep 1, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/88
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.